239 related articles for article (PubMed ID: 22027607)
21. [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
Levin OS; Ivanov AK; Shindriaeva NN
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(1):38-42. PubMed ID: 21350410
[TBL] [Abstract][Full Text] [Related]
22. Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.
Lyons KE; Pahwa R
Clin Neuropharmacol; 2006; 29(2):73-6. PubMed ID: 16614538
[TBL] [Abstract][Full Text] [Related]
23. Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.
Eggert K; Skogar O; Amar K; Luotonen L; Kuoppamäki M; Leinonen M; Nissinen H; Oertel W
J Neural Transm (Vienna); 2010 Mar; 117(3):333-42. PubMed ID: 20013007
[TBL] [Abstract][Full Text] [Related]
24. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
[TBL] [Abstract][Full Text] [Related]
25. [Nocturnal symptoms of Parkinson's disease and approaches to their correction].
Kulua TK; Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):62-6. PubMed ID: 24430037
[TBL] [Abstract][Full Text] [Related]
26. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacotherapy of motor manifestations in late stages of Parkinson's disease].
Bogdanov RR; Kotov SV; Kunitsyna AN; Turbina LG
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(11 Pt 1):21-5. PubMed ID: 21183918
[TBL] [Abstract][Full Text] [Related]
29. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
[TBL] [Abstract][Full Text] [Related]
30. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Liashchenko EA; Skripkina NA; Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
[TBL] [Abstract][Full Text] [Related]
31. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
[TBL] [Abstract][Full Text] [Related]
32. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
33. Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study).
Myllylä V; Haapaniemi T; Kaakkola S; Kinnunen E; Hartikainen P; Nuutinen J; Rissanen A; Kuopio AM; Jolma T; Satomaa O; Heikkinen H
Acta Neurol Scand; 2006 Sep; 114(3):181-6. PubMed ID: 16911346
[TBL] [Abstract][Full Text] [Related]
34. Stalevo for Parkinson's disease.
Med Lett Drugs Ther; 2004 May; 46(1182):39-40. PubMed ID: 15136772
[No Abstract] [Full Text] [Related]
35. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.
Smith LA; Jackson MJ; Al-Barghouthy G; Rose S; Kuoppamaki M; Olanow W; Jenner P
Mov Disord; 2005 Mar; 20(3):306-14. PubMed ID: 15490461
[TBL] [Abstract][Full Text] [Related]
36. [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].
Fedotova EIu; Karabanov AV; Poleshchuk VV; Polevaia EV; Mirkasimov AF; Zagorovskaia TB; Ivanova-Smolenskaia IA; Illarioshkin SN
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5):50-5. PubMed ID: 22951782
[TBL] [Abstract][Full Text] [Related]
37. Entacapone/levodopa/carbidopa combination tablet: Stalevo.
Drugs R D; 2003; 4(5):310-1. PubMed ID: 12952501
[TBL] [Abstract][Full Text] [Related]
38. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
40. [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
Boĭko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EIu; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaĭtsev KA; Kostenko EV
Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):21-4. PubMed ID: 18427455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
